MOSUNETUZUMAB-AXGB: 198 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
198
Total FAERS Reports
13 (6.6%)
Deaths Reported
48
Hospitalizations
198
As Primary/Secondary Suspect
3
Life-Threatening
1
Disabilities
Prescription
Status
FDA Application: 761263 ·
First Report: 20190101 · Latest Report: 20250822
What Are the Most Common MOSUNETUZUMAB-AXGB Side Effects?
#1 Most Reported
Cytokine release syndrome
52 reports (26.3%)
#2 Most Reported
Pyrexia
27 reports (13.6%)
#3 Most Reported
Disease progression
25 reports (12.6%)
All MOSUNETUZUMAB-AXGB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Cytokine release syndrome | 52 | 26.3% | 2 | 23 |
| Pyrexia | 27 | 13.6% | 0 | 16 |
| Disease progression | 25 | 12.6% | 2 | 9 |
| Off label use | 20 | 10.1% | 0 | 2 |
| Rash | 18 | 9.1% | 0 | 1 |
| No adverse event | 16 | 8.1% | 0 | 0 |
| Neutropenia | 13 | 6.6% | 1 | 1 |
| Thrombocytopenia | 9 | 4.6% | 0 | 0 |
| Chills | 8 | 4.0% | 0 | 2 |
| Fatigue | 8 | 4.0% | 0 | 3 |
| Death | 7 | 3.5% | 7 | 1 |
| Headache | 7 | 3.5% | 0 | 2 |
| Klebsiella test positive | 7 | 3.5% | 0 | 7 |
| Leukopenia | 7 | 3.5% | 0 | 0 |
| Vomiting | 7 | 3.5% | 0 | 2 |
| Acetabulum fracture | 6 | 3.0% | 0 | 0 |
| Anaphylactic shock | 6 | 3.0% | 0 | 0 |
| Drug ineffective | 6 | 3.0% | 0 | 1 |
| Nausea | 6 | 3.0% | 0 | 2 |
| Splenomegaly | 6 | 3.0% | 0 | 0 |
Who Reports MOSUNETUZUMAB-AXGB Side Effects? Age & Gender Data
Gender: 56.1% female, 43.9% male. Average age: 63.5 years. Most reports from: US. View detailed demographics →
Is MOSUNETUZUMAB-AXGB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 0 |
| 2022 | 3 | 0 | 0 |
| 2023 | 24 | 1 | 4 |
| 2024 | 21 | 0 | 6 |
| 2025 | 12 | 1 | 7 |
What Is MOSUNETUZUMAB-AXGB Used For?
| Indication | Reports |
|---|---|
| Follicular lymphoma | 126 |
| Product used for unknown indication | 41 |
| Diffuse large b-cell lymphoma | 9 |
| Follicular lymphoma refractory | 5 |
MOSUNETUZUMAB-AXGB vs Alternatives: Which Is Safer?
MOSUNETUZUMAB-AXGB vs MOXIFLOXACIN
MOSUNETUZUMAB-AXGB vs MOXIFLOXACIN\MOXIFLOXACIN
MOSUNETUZUMAB-AXGB vs MOXONIDINE
MOSUNETUZUMAB-AXGB vs MS CONTIN
MOSUNETUZUMAB-AXGB vs MULTAQ
MOSUNETUZUMAB-AXGB vs MULTIHANCE
MOSUNETUZUMAB-AXGB vs MUPIROCIN
MOSUNETUZUMAB-AXGB vs MUPIROCIN\MUPIROCIN
MOSUNETUZUMAB-AXGB vs MUROMONAB-CD3
MOSUNETUZUMAB-AXGB vs MYCOPHENOLATE
Official FDA Label for MOSUNETUZUMAB-AXGB
Official prescribing information from the FDA-approved drug label.